Good Health Can’t Wait.

Standalone Financial Statements Annual Report 2014 - 15
NOTES TO FINANCIAL STATEMENTS
(All amounts in Indian Rupees millions, except share data and where otherwise stated)
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
PARTICULARS
FOR THE YEAR ENDED
31 MARCH 2015
FOR THE YEAR ENDED
31 MARCH 2014
xxiv. Guarantee given / (released) on behalf of subsidiary and step down subsidiary:
Dr.Reddy’s Laboratories SA (3,295) (407)
Reddy Holding GmbH - (3,266)
Dr.Reddy’s Laboratories Inc. - (75)
Dr. Reddy’s Venezuela C.A. (539) -
Effect of changes in the foreign exchange rates 417 1,309
Total (3,417) (2,439)
e. The Company has the following amounts due from / to related parties:
PARTICULARS
AS AT
31MARCH 2015
AS AT
31MARCH 2014
i. Due from related parties:
Subsidiaries including step down subsidiaries (included in trade receivables):
Dr.Reddy’s Laboratories Inc. 25,619 21,224
OOO Dr.Reddy’s Laboratories Limited 5,758 9,918
Others 8,349 6,693
Total 39,726 37,835
Rental deposit to key management personnel and their relatives 8 8
ii. Provision outstanding at the end of the year towards dues from subsidiaries including step
down subsidiaries (included in trade receivables):
Reddy Cheminor S.A. 5 5
OOO Dr. Reddy’s Laboratories Limited 7 7
Total 12 12
iii. Due to related parties:
Subsidiaries including step down subsidiaries (included in trade payables and other
current liabilities):
Dr. Reddy’s Laboratories Inc. 1,718 429
OOO Dr. Reddy’s Laboratories Limited 798 1,620
Reddy Netherlands B.V. - 992
Dr. Reddy’s Laboratories SA 320 314
OctoPlus Development B.V. 535 8
Others 365 597
Total 3,736 3,960
Others (included in trade payables and other current liabilities):
Dr.Reddy’s Research Foundation 18 18
Green Park Hotels & Resorts Limited 1 -
Dr. Reddy’s Institute of Life Sciences 3 -
Total 22 18
Equity held in subsidiaries, associates and joint venture has been disclosed under “Non current investments” (Note 2.8). Loans and advances to subsidiaries,
joint venture and associates have been disclosed under “Long term loans and advances” (Note 2.9). Other receivables from subsidiaries, associates and
joint venture have been disclosed under “Other current assets” (Note 2.15).
145